NASDAQ:VYNE

VYNE Therapeutics Stock Forecast, Price & News

$2.70

0.00 (0.00 %)

(As of 07/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.64

▼

$2.81

50-Day Range

$2.69

▼

$4.11

52-Week Range

$2.62

▼

$13.20

Volume306,994 shs

Average Volume584,226 shs

Market Capitalization$138.75 million

P/E RatioN/A

Dividend YieldN/A

Beta0.75

30 days | 90 days | 365 days | Advanced Chart

Receive VYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About VYNE Therapeutics

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc. (NASDAQ:VYNE) Receives Average Recommendation of "Buy" from Brokerages
July 20, 2021 | americanbankingnews.com

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
July 19, 2021 | finance.yahoo.com

Contrasting VYNE Therapeutics (NASDAQ:VYNE) & Kiniksa Pharmaceuticals (NASDAQ:KNSA)
July 19, 2021 | americanbankingnews.com

VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Drop in Short Interest
July 19, 2021 | americanbankingnews.com

$6.19 Million in Sales Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter
July 18, 2021 | americanbankingnews.com

-$0.35 Earnings Per Share Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter
July 16, 2021 | americanbankingnews.com

What You Need To Know About VYNE Therapeutics Inc.'s (NASDAQ:VYNE) Investor Composition
July 14, 2021 | nasdaq.com

BRIEF-Vyne Therapeutics Says On June 30 Received A Paragraph IV Certification Notice From Perrigo Israel Pharmaceuticals
July 2, 2021 | msn.com

VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event
June 29, 2021 | finance.yahoo.com

VYNE Therapeutics Inc.
June 10, 2021 | barrons.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYNE
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.menlotherapeutics.com
Phone800-775-7936
Employees106
Year FoundedN/A

Sales & Book Value

Annual Sales$20.99 million
Price / Sales6.61
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.89 per share
Price / Book3.03

Profitability

EPS (Most Recent Fiscal Year)($7.88)
Net Income$-255,570,000.00
Net Margins-1,009.70%
Return on Equity-375.26%
Return on Assets-195.98%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares51,390,000
Market Cap$138.75 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.51 out of 5 stars

Medical Sector

1195th out of 4,434 stocks

Pharmaceutical Preparations Industry

577th out of 1,738 stocks

3.5 Analyst's Opinion

Consensus Rating
VYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, VYNE Therapeutics has a forecasted upside of 677.8% from its current price of $2.70.
Amount of Analyst Coverage
VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
VYNE Therapeutics has received 9 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
VYNE Therapeutics has received 8 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
VYNE Therapeutics has received 52.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about VYNE Therapeutics and other stocks. Vote “Outperform” if you believe VYNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
VYNE Therapeutics does not currently pay a dividend.
Dividend Growth
VYNE Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VYNE Therapeutics insiders have sold 8,055.56% more of their company's stock than they have bought. Specifically, they have bought $45,000.00 in company stock and sold $3,670,000.00 in company stock.
Percentage Held by Insiders
Only 2.80% of the stock of VYNE Therapeutics is held by insiders.
Percentage Held by Institutions
43.85% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for VYNE Therapeutics are expected to grow in the coming year, from ($1.37) to ($0.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VYNE Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VYNE Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VYNE Therapeutics has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

VYNE Therapeutics (NASDAQ:VYNE) Frequently Asked Questions

Is VYNE Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNE Therapeutics stock.
View analyst ratings for VYNE Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than VYNE Therapeutics?

Wall Street analysts have given VYNE Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VYNE Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 2,570,000 shares, a decrease of 35.6% from the June 15th total of 3,990,000 shares. Based on an average trading volume of 924,700 shares, the short-interest ratio is presently 2.8 days. Currently, 5.1% of the company's shares are short sold.
View VYNE Therapeutics' Short Interest.

When is VYNE Therapeutics' next earnings date?

VYNE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for VYNE Therapeutics.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its earnings results on Thursday, May, 6th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.47) by $0.10. The business had revenue of $4.12 million for the quarter, compared to the consensus estimate of $5.08 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 375.26% and a negative net margin of 1,009.70%.
View VYNE Therapeutics' earnings history.

How has VYNE Therapeutics' stock price been impacted by Coronavirus?

VYNE Therapeutics' stock was trading at $13.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VYNE shares have decreased by 79.5% and is now trading at $2.70.
View which stocks have been most impacted by COVID-19.

When did VYNE Therapeutics' stock split? How did VYNE Therapeutics' stock split work?

VYNE Therapeutics's stock reverse split on Tuesday, February 16th 2021. The 1-4 reverse split was announced on Thursday, February 11th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 15th 2021. An investor that had 100 shares of VYNE Therapeutics stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for VYNE?

5 analysts have issued 12 month target prices for VYNE Therapeutics' stock. Their forecasts range from $11.00 to $28.00. On average, they expect VYNE Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 677.8% from the stock's current price.
View analysts' price targets for VYNE Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VYNE Therapeutics' key executives?

VYNE Therapeutics' management team includes the following people:

Mr. David T. Domzalski, CEO, Pres & Director (Age 54, Pay $907.72k)
Ms. Mutya Harsch, Gen. Counsel, Chief Legal Officer & Company Sec. (Age 46, Pay $523.26k)
Mr. Tyler Zeronda, Interim CFO, Principal Accounting Officer & Treasurer (Age 35)
Dr. Iain A. Stuart, Chief Scientific Officer (Age 48)
Mr. Raymond G. Steitz, Sr. VP of Global HR (Age 62)
Dr. Russell Elliott, Sr. VP of Pharmaceutical Devel. (Age 55)
Mr. Matthew Wiley, Chief Commercial Officer (Age 49)
Dr. Darrell S. Rigel M.S., M.D., MS, Consultant (Age 71)

Who are some of VYNE Therapeutics' key competitors?

Some companies that are related to VYNE Therapeutics include Veru (VERU), VistaGen Therapeutics (VTGN), AC Immune (ACIU), Greenwich LifeSciences (GLSI), Inventiva (IVA), Spectrum Pharmaceuticals (SPPI), Aldeyra Therapeutics (ALDX), DiaMedica Therapeutics (DMCAF), KalVista Pharmaceuticals (KALV), Imago BioSciences (IMGO), Clovis Oncology (CLVS), Atossa Therapeutics (ATOS), Werewolf Therapeutics (HOWL), Vaccitech (VACC) and Evelo Biosciences (EVLO).
View all of VYNE's competitors.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

How do I buy shares of VYNE Therapeutics?

Shares of VYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $2.70.

How much money does VYNE Therapeutics make?

VYNE Therapeutics has a market capitalization of $138.75 million and generates $20.99 million in revenue each year. The company earns $-255,570,000.00 in net income (profit) each year or ($7.88) on an earnings per share basis.

How many employees does VYNE Therapeutics have?

VYNE Therapeutics employs 106 workers across the globe.

What is VYNE Therapeutics' official website?

The official website for VYNE Therapeutics is www.menlotherapeutics.com.

Where are VYNE Therapeutics' headquarters?

VYNE Therapeutics is headquartered at 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at 800-775-7936 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here